1-2 of 2
Judit Jørgensen
Close
Sort by
Journal Articles

Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy

Joachim Baech, Marianne Tang Severinsen, Andreas K. Øvlisen, Henrik Frederiksen, Peter Vestergaard, Christian Torp-Pedersen, Judit Jørgensen, Michael Roost Clausen, Christian B. Poulsen, Peter Brown, Anne Ortved Gang, Robert Schou Pedersen, Karin Ekström Smedby, Sandra Eloranta, Lasse Hjort Jakobsen, Tarec Christoffer El-Galaly
Journal: Blood Advances
Blood Adv (2022) 6 (15): 4427–4435.
https://doi.org/10.1182/bloodadvances.2021006859
Published: 2022
Includes: Supplemental data
Journal Articles

Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

Clinical Trials & Observations
Sirpa Leppä, Judit Jørgensen, Anne Tierens, Leo Meriranta, Ingunn Østlie, Peter de Nully Brown, Unn-Merete Fagerli, Thomas Stauffer Larsen, Susanna Mannisto, Lars Munksgaard, Martin Maisenhölder, Kaija Vasala, Peter Meyer, Mats Jerkeman, Magnus Björkholm, Øystein Fluge, Sirkku Jyrkkiö, Knut Liestøl, Elisabeth Ralfkiaer, Signe Spetalen, Klaus Beiske, Marja-Liisa Karjalainen-Lindsberg, Harald Holte
Journal: Blood Advances
Blood Adv (2020) 4 (9): 1906–1915.
https://doi.org/10.1182/bloodadvances.2020001518
Published: 2020
Includes: Supplemental data